Hims & Hers
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.
Through the acquisition, the company will expand its operations in the UK and launch operations in Germany, France and Ireland.
Americans with a prescription will have access to Novo Nordisk's obesity drug Wegovy through the Hims & Hers platform for $599 monthly.
The aim is to offer a broader range of personalized treatment options to patients.
Two U.S. senators and the Partnership for Safe Medicines sent letters to the FDA, raising concerns that the ad fails to disclose safety and side effect information required in pharmaceutical advertising.
The company reported a 77% YOY increase in revenue in Q3 2024 and plans to release a generic version of Novo Nordisk's GLP-1 drug on its platform in 2025.
Talkspace also announced a 29% year-over-year revenue growth in the second quarter, and Clover Health reported an 11% increase in revenue.
The company said its drugs will be more accessible than brand-name versions thanks to a partnership with a manufacturer of generic and 503B compounded injectables.
The virtual care company reported a 65% increase in revenue in 2023 compared to 2022 and a 47% increase in Q4 2023 revenue compared to the previous year.
Execs overwhelmingly cite genAI as having the most significant impact in healthcare this year, though others provide alternative takes on the years' events.